Travere Therapeutics, Inc.

TVTX · Nasdaq · United States

Share price · TVTX

$50.24-13.66 (-21.38%) 3M

close as of 2026-11-18 · 24h delayed · vol 884K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TVTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Sep 2026-4.1%
  2. 5 Aug 2026+12.0%
  3. 14 Apr 2026+37.2%
  4. 13 Feb 2026-9.1%
  5. 13 Jan 2026-14.6%

    Nothing announced by TVTX that day or the session before.

  6. 6 Jan 2026-6.1%
  7. 24 Dec 2025+13.9%

    Nothing announced by TVTX that day or the session before.

Share of unusual movement by asset

For each asset, the share of TVTX's own-move activity since 10 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
sparsentan (Filspari)
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—36%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—58%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
sparsentan(Filspari)
Approved
Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule
Focal Segmental GlomerulosclerosisIgA Nephropathy

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
sparsentan · FilspariPhase 2Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Est. primary completion 2027-03-12 · NCT05003986 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 April 2026ApprovalsparsentanFDA approves FILSPARI for FSGS
US, FDA · Source ↗
5 September 2024ApprovalsparsentanFDA grants full approval of Filspari in IgA nephropathy
US, FDA · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$225M$70M$124M+ $180M short-term inv.$52M$98M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$170M$60M$118M+ $176M short-term inv.$35M$58M operating cash flowreport ↗
2026-Q1$127M$57M$78M+ $131M short-term inv.$37M-$40M operating cash flowreport ↗
2025-Q3$165M$52M$111M+ $139M short-term inv.—$14M operating cash flowreport ↗
2025-Q2$114M$49M$75M$13M$5.0M operating cash flowreport ↗
2025-Q1$82M$47M$62M$41M-$42M operating cash flowreport ↗
2024-Q3$63M$52M$36M+ $219M short-term inv.$55M-$43M operating cash flowreport ↗
2024-Q2$54M$54M$32M+ $222M short-term inv.$70M-$40M operating cash flowreport ↗
2024-Q1$41M$49M$43M+ $241M short-term inv.$136M-$119M operating cash flowreport ↗
2023-Q4$45M—$58M+ $249M short-term inv.$90M-$70M operating cash flowreport ↗
2023-Q3$37M$61M$144M+ $213M short-term inv.—-$59M operating cash flowreport ↗
2023-Q2$60M$69M$71M+ $231M short-term inv.$86M-$69M operating cash flowreport ↗
2023-Q1$57M$60M$161M+ $279M short-term inv.$86M-$81M operating cash flowreport ↗
2022-Q4$29M—$62M+ $286M short-term inv.$66M-$55M operating cash flowreport ↗
2022-Q3$54M$59M$151M+ $297M short-term inv.$70M-$40M operating cash flowreport ↗
2022-Q2$54M$60M$180M+ $329M short-term inv.$67M-$37M operating cash flowreport ↗
2022-Q1$48M$57M$257M+ $273M short-term inv.$76M-$55M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$491M$206M$93M+ $145M short-term inv.$6.4M$38M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$233M$218M$59M$80M-$237M operating cash flowreport ↗
2023-FY$145M$245M$58M+ $249M short-term inv.$28M-$280M operating cash flowreport ↗
2022-FY$212M$236M$62M+ $286M short-term inv.$70M-$186M operating cash flowreport ↗
2021-FY$227M$210M$166M+ $262M short-term inv.$45M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 118 sales ($110.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROption exercise43,735$26.88$1.2MForm 4
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROption exercise200,000$8.93$1.8MForm 4
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROpen-market sale128,065$52.97$6.8MForm 4
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROpen-market sale37,270$54.20$2.0MForm 4
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROpen-market sale78,400$55.02$4.3MForm 4
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROption exercise (derivative)43,735——Form 4
2026-10-15Dube Eric M · director, CHIEF EXECUTIVE OFFICEROption exercise (derivative)200,000——Form 4
2026-09-17Dube Eric M · director, CHIEF EXECUTIVE OFFICEROption exercise108,493$23.34$2.5MForm 4